Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Renal Cell 11Carcinoma, Hepatocellular 10Parkinson Disease 4, Autosomal Dominant Lewy Body 6Neoplasms 6Melanoma 4Endometrial Neoplasms 3Uveal Melanoma 2Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Liver Neoplasms 2Kidney Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Carcinoma, Adenoid Cystic 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Clear Cell Carcinoma 1Non-squamous Non-small-cell Lung Cancer 1NSCLC 1Multiple Endocrine Neoplasia Type 1 1Mesothelioma, Malignant 1

Interventions

pembrolizumab 1lenvatinib 1Pemetrexed 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Non-squamous Non-small-cell Lung Cancer × lenvatinib × Clear all
NCT05258279 2024-08-28

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

Juntendo University

Phase 2 Active not recruiting
30 enrolled
Thoracic

Non-squamous Non-small-cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡